Abbvie Inc Stock Price, News & Analysis

AbbVie announced that the European Commission approved RINVOQ™ (upadacitinib) for treating active psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in adults. RINVOQ is an oral, once-daily JAK inhibitor for patients who have not responded to DMARDs. The approval is based on pivotal trials demonstrating RINVOQ's efficacy, including significant improvements in physical function and disease activity scores. Safety profiles align with findings from rheumatoid arthritis studies. RINVOQ is now authorized for use across EU member states and other associated countries.

Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced the presentation of 16 abstracts at the TOXINS 2021 Virtual Conference on January 16-17. These abstracts cover the efficacy and safety of BOTOX® across various therapeutic and cosmetic uses. Key studies include long-term immunogenicity rates, adherence in patients with spasticity, and treatment satisfaction in patients with dynamic glabellar lines. The findings will be published in Toxicon and available for six months post-conference, enhancing understanding of onabotulinumtoxinA's comprehensive benefits.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a warrant agreement with Cypris Medical to potentially acquire the company following a clinical trial in 2021. The trial will assess the Xact device's safety and efficacy for treating midface descent and neck lifts. Designed as a minimally invasive alternative, Xact aims to deliver surgery-like results with minimal downtime. This partnership enhances Allergan's portfolio of aesthetic products, fulfilling the increasing demand for non-invasive treatments.

AbbVie (NYSE: ABBV) will report its fourth-quarter and full-year 2020 financial results on February 3, 2021, before the market opens. A live webcast of the earnings conference call is scheduled for 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived version of the call will be available later that day. AbbVie is committed to creating innovative treatments in various therapeutic areas, including immunology, oncology, neuroscience, and more.

Dragonfly Therapeutics has announced the first opt-in from AbbVie for a TriNKET™ drug candidate as part of a collaboration initiated in November 2019. This partnership aims to develop novel immunotherapies targeting autoimmune and oncology diseases. AbbVie will gain exclusive worldwide rights to develop and commercialize the candidate, while Dragonfly will receive an opt-in payment along with potential future milestone payments and royalties on sales. Both companies express optimism about future collaborations and advancements in treatment options.

AbbVie (NYSE: ABBV) announced successful results from two Phase 3 studies, ADVANCE and MOTIVATE, for risankizumab in treating moderate to severe Crohn's disease. Both doses (600 mg and 1200 mg) achieved primary endpoints of clinical remission and endoscopic response by week 12. In the ADVANCE study, 45% and 42% of patients achieved clinical remission compared to 25% on placebo (p<0.001). Similarly, the MOTIVATE study showed 42% and 41% for risankizumab against 19% for placebo. The safety profile remains consistent, with no new risks identified among treatment groups.

AbbVie will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. The event will feature presentations from key executives including Richard A. Gonzalez, Michael Severino, Robert A. Michael, and Jeffrey R. Stewart. The presentation is scheduled for 3:30 p.m. Central time and will be accessible via a live audio webcast on AbbVie's Investor Relations website. An archived version will be available later that same day.

AbbVie focuses on innovative medicines across multiple therapeutic areas, including immunology, oncology, and neuroscience.

AbbVie announced positive results from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, evaluating risankizumab (150 mg) for adults with active psoriatic arthritis. At week 24, 57% and 51% of patients achieved the ACR20 response in KEEPsAKE-1 and KEEPsAKE-2, respectively, compared to 34% and 27% with placebo (p<0.001). Secondary endpoints also showed significant improvements in skin clearance and physical function. The safety profile was consistent with previous studies, with serious adverse events occurring in 2.5% and 4.0% of patients on risankizumab.

AbbVie has announced FDA approval for updated prescribing information for IMBRUVICA (ibrutinib) to include long-term efficacy and safety data for its combination use with rituximab in treating Waldenström's macroglobulinemia (WM). This update is based on the final analysis of the Phase 3 iNNOVATE study, demonstrating a 75% reduction in the risk of disease progression or death. IMBRUVICA remains the only FDA-approved treatment for WM, reinforcing AbbVie's commitment to blood cancer patients.